Crinetics Submits Palsonify MAA in Brazil, Expanding Global Reach for Acromegaly Treatment
CRNX sits 51% above its 52-week low of $24.1.
Summary
Crinetics Pharmaceuticals has announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health Surveillance Agency (ANVISA) for Palsonify (paltusotine) to treat acromegaly. This move follows the product's recent FDA approval in the US and a positive regulatory opinion in Europe, marking a significant step in the global commercialization strategy for their lead asset. The submission is supported by comprehensive clinical data, including two positive Phase 3 trials. This expansion into the Brazilian market is a positive development, indicating continued growth potential and broader market access for Palsonify, which began generating revenue in Q4 2025. Traders will now watch for updates on the regulatory review process in Brazil and potential approval.
At the time of this announcement, CRNX was trading at $36.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $24.10 to $57.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.